Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen - PubMed (original) (raw)

Clinical Trial

. 2007 Aug 1;110(3):1055-63.

doi: 10.1182/blood-2007-02-075911. Epub 2007 Apr 4.

Yoshiki Akatsuka, Hiroki Torikai, Satoko Morishima, Akira Oka, Akane Tsujimura, Mikinori Miyazaki, Kunio Tsujimura, Koichi Miyamura, Seishi Ogawa, Hidetoshi Inoko, Yasuo Morishima, Yoshihisa Kodera, Kiyotaka Kuzushima, Toshitada Takahashi

Affiliations

Free article

Clinical Trial

Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen

Takakazu Kawase et al. Blood. 2007.

Free article

Abstract

Here we report the identification of a novel human leukocyte antigen (HLA)-B44-restricted minor histocompatibility antigen (mHA) with expression limited to hematopoietic cells. cDNA expression cloning studies demonstrated that the cytotoxic T lymphocyte (CTL) epitope of interest was encoded by a novel allelic splice variant of HMSD, hereafter designated as HMSD-v. The immunogenicity of the epitope was generated by differential protein expression due to alternative splicing, which was completely controlled by 1 intronic single-nucleotide polymorphism located in the consensus 5' splice site adjacent to an exon. Both HMSD-v and HMSD transcripts were selectively expressed at higher levels in mature dendritic cells and primary leukemia cells, especially those of myeloid lineage. Engraftment of mHA(+) myeloid leukemia stem cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID)/gammac(null) mice was completely inhibited by in vitro preincubation with the mHA-specific CTL clone, suggesting that this mHA is expressed on leukemic stem cells. The patient from whom the CTL clone was isolated demonstrated a significant increase of the mHA-specific T cells in posttransplantation peripheral blood, whereas mHA-specific T cells were undetectable in pretransplantation peripheral blood and in peripheral blood from his donor. These findings suggest that the HMSD-v-encoded mHA (designated ACC-6) could serve as a target antigen for immunotherapy against hematologic malignancies.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources